Profile - To The Moon

Tendious

Posts · 4Posts · 4
Following · 0Following · 0
Followers · 0Followers · 0

- TendiousTendious
  ·2021-06-22
  Awesome article. Vroom vroom.
  Nissan CEO says performance for April, May better than expected
  TOKYO (Reuters) - Nissan Motor Co's financial performance in April and May was better than expected,
  Nissan CEO says performance for April, May better than expected
  274 2
  4
  Share
  Report
- TendiousTendious
  ·2021-06-20
  Cool article. Get vaccinated!
  AstraZeneca must use Britain's plant if needed to meet EU's vaccine commitments - EU lawyer
  June 18 (Reuters) - AstraZeneca must deliver COVID-19 vaccines to the European Union also from a fac
  AstraZeneca must use Britain's plant if needed to meet EU's vaccine commitments - EU lawyer
  26 Comment
  2
  Share
  Report
- TendiousTendious
  ·2021-06-19
  Good read. Cheers.
  Next Market Crash: 2 Top Growth Stocks to Buy Right Now
  Don't wait to jump on this red-hot tech company and unstoppable dividend stock.
  Next Market Crash: 2 Top Growth Stocks to Buy Right Now
  37 Comment
  3
  Share
  Report
- TendiousTendious
  ·2021-06-15
  Good buy like and comment!
  Apple Plans Faster Watch, Future Temperature and Glucose Sensors
  Updated screens and performance this year, new functions later. New entry-level and extreme sports models planned for 2022. A customer tries on an Apple watch at a store in Palo Alto, California. Photographer: Nina Riggio/Bloomberg. Apple Inc. is working on new Apple Watch models and health features, spanning display and speed upgrades, an extreme sports edition and body temperature and blood sugar sensors.The Cupertino, California-based tech giant is planning to refresh the line this year -- wi
  Apple Plans Faster Watch, Future Temperature and Glucose Sensors
  85 Comment
  1
  Share
  Report
No followers yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3586403806630485","uuid":"3586403806630485","gmtCreate":1623309782086,"gmtModify":1623729164692,"name":"Tendious","pinyin":"tendious","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/0ec0679eb8bdffa05ed9e8b48dec1986","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":169,"tweetSize":4,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.07.03","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":120750118,"gmtCreate":1624338856734,"gmtModify":1703833916894,"author":{"id":"3586403806630485","authorId":"3586403806630485","name":"Tendious","avatar":"https://static.tigerbbs.com/0ec0679eb8bdffa05ed9e8b48dec1986","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586403806630485","authorIdStr":"3586403806630485"},"themes":[],"htmlText":"Awesome article. Vroom vroom.&nbsp;","listText":"Awesome article. Vroom vroom.&nbsp;","text":"Awesome article. Vroom vroom.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/120750118","repostId":"2145757030","repostType":4,"repost":{"id":"2145757030","pubTimestamp":1624337760,"share":"https://ttm.financial/m/news/2145757030?lang=&edition=fundamental","pubTime":"2021-06-22 12:56","market":"us","language":"en","title":"Nissan CEO says performance for April, May better than expected","url":"https://stock-news.laohu8.com/highlight/detail?id=2145757030","media":"StreetInsider","summary":"TOKYO (Reuters) - Nissan Motor Co's financial performance in April and May was better than expected,","content":"<p>TOKYO (Reuters) - Nissan Motor Co's financial performance in April and May was better than expected, the automaker's president said at the annual general meeting (AGM) on Tuesday.</p>\n<p>The announcement to shareholders came after the automaker's forecast last month that its sales would break even for the fiscal year that began on April 1.</p>\n<p>\"But we already see signs of recovery,\" said Nissan's Chief Executive Officer Uchida. \"Thanks to the strong results of our ongoing efforts over the past year, Nissan's performance for April and May is better than our plan.\"</p>\n<p>The global Nissan team is \"doing everything it can\" to avoid three consecutive years of losses, Uchida said.</p>\n<p>Nissan, like other automakers, has been making production adjustments because of a global chip supply crunch. Sources have told Reuters the company would temporarily halt production at some plants in Japan and Mexico this month.</p>\n<p>\"As we pay close attention to the market trends and adjust production of models, we are minimising the negative impact of the semiconductor supply issue on the plant utilisation rate,\" Uchida said.</p>\n<p>He added that the company was trying to make up for the production loss within the financial year and to take action to ensure stability in its supply of parts.</p>\n<p>Although the company is not ready to provide dividend forecasts, it will try to generate sufficient net cash and resume payments as soon as possible, Uchida said.</p>\n<p>When a shareholder asked about a domestic media report last week that the automaker is ending the development of its Skyline sedans, Uchida said that Nissan has made no such decision.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nissan CEO says performance for April, May better than expected</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNissan CEO says performance for April, May better than expected\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-22 12:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18585925><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>TOKYO (Reuters) - Nissan Motor Co's financial performance in April and May was better than expected, the automaker's president said at the annual general meeting (AGM) on Tuesday.\nThe announcement to ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18585925\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NSANY":"日产汽车"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18585925","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145757030","content_text":"TOKYO (Reuters) - Nissan Motor Co's financial performance in April and May was better than expected, the automaker's president said at the annual general meeting (AGM) on Tuesday.\nThe announcement to shareholders came after the automaker's forecast last month that its sales would break even for the fiscal year that began on April 1.\n\"But we already see signs of recovery,\" said Nissan's Chief Executive Officer Uchida. \"Thanks to the strong results of our ongoing efforts over the past year, Nissan's performance for April and May is better than our plan.\"\nThe global Nissan team is \"doing everything it can\" to avoid three consecutive years of losses, Uchida said.\nNissan, like other automakers, has been making production adjustments because of a global chip supply crunch. Sources have told Reuters the company would temporarily halt production at some plants in Japan and Mexico this month.\n\"As we pay close attention to the market trends and adjust production of models, we are minimising the negative impact of the semiconductor supply issue on the plant utilisation rate,\" Uchida said.\nHe added that the company was trying to make up for the production loss within the financial year and to take action to ensure stability in its supply of parts.\nAlthough the company is not ready to provide dividend forecasts, it will try to generate sufficient net cash and resume payments as soon as possible, Uchida said.\nWhen a shareholder asked about a domestic media report last week that the automaker is ending the development of its Skyline sedans, Uchida said that Nissan has made no such decision.","news_type":1},"isVote":1,"tweetType":1,"viewCount":274,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3572862825709578","authorId":"3572862825709578","name":"edwardchiw","avatar":"https://static.tigerbbs.com/d75ed25410ef7612e0bffe49406e2c9a","crmLevel":1,"crmLevelSwitch":0,"idStr":"3572862825709578","authorIdStr":"3572862825709578"},"content":"Kindly help to like and reply","text":"Kindly help to like and reply","html":"Kindly help to like and reply"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":164949434,"gmtCreate":1624168191928,"gmtModify":1703830041886,"author":{"id":"3586403806630485","authorId":"3586403806630485","name":"Tendious","avatar":"https://static.tigerbbs.com/0ec0679eb8bdffa05ed9e8b48dec1986","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586403806630485","authorIdStr":"3586403806630485"},"themes":[],"htmlText":"Cool article. Get vaccinated!","listText":"Cool article. Get vaccinated!","text":"Cool article. Get vaccinated!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/164949434","repostId":"2144771068","repostType":4,"repost":{"id":"2144771068","pubTimestamp":1624026418,"share":"https://ttm.financial/m/news/2144771068?lang=&edition=fundamental","pubTime":"2021-06-18 22:26","market":"us","language":"en","title":"AstraZeneca must use Britain's plant if needed to meet EU's vaccine commitments - EU lawyer","url":"https://stock-news.laohu8.com/highlight/detail?id=2144771068","media":"Reuters","summary":"June 18 (Reuters) - AstraZeneca must deliver COVID-19 vaccines to the European Union also from a fac","content":"<p>June 18 (Reuters) - AstraZeneca must deliver COVID-19 vaccines to the European Union also from a factory in Britain if it is needed to meet its commitments with the EU, a judge ruled on Friday, according to a lawyer representing the EU.</p>\n<p>The company had said it could not immediately deliver to the EU doses from an Oxford Biomedica factory in Britain because it had to supply the United Kingdom first.</p>\n<p>The EU lawyer said the judge decided that that factory must be used for EU supplies. However, AstraZeneca could meet its commitments with the EU without using that factory.</p>\n<p>The company is not obliged to deliver doses by a timetable in the contract until the end of June, but must still deliver a total of 300 million doses to the EU, the judge ruled. (Reporting by Francesco Guarascio @fraguarascio, editing by Louise Heavens)</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca must use Britain's plant if needed to meet EU's vaccine commitments - EU lawyer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca must use Britain's plant if needed to meet EU's vaccine commitments - EU lawyer\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-18 22:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/astrazeneca-must-britains-plant-needed-132658433.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>June 18 (Reuters) - AstraZeneca must deliver COVID-19 vaccines to the European Union also from a factory in Britain if it is needed to meet its commitments with the EU, a judge ruled on Friday, ...</p>\n\n<a href=\"https://finance.yahoo.com/news/astrazeneca-must-britains-plant-needed-132658433.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN":"阿斯利康"},"source_url":"https://finance.yahoo.com/news/astrazeneca-must-britains-plant-needed-132658433.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2144771068","content_text":"June 18 (Reuters) - AstraZeneca must deliver COVID-19 vaccines to the European Union also from a factory in Britain if it is needed to meet its commitments with the EU, a judge ruled on Friday, according to a lawyer representing the EU.\nThe company had said it could not immediately deliver to the EU doses from an Oxford Biomedica factory in Britain because it had to supply the United Kingdom first.\nThe EU lawyer said the judge decided that that factory must be used for EU supplies. However, AstraZeneca could meet its commitments with the EU without using that factory.\nThe company is not obliged to deliver doses by a timetable in the contract until the end of June, but must still deliver a total of 300 million doses to the EU, the judge ruled. (Reporting by Francesco Guarascio @fraguarascio, editing by Louise Heavens)","news_type":1},"isVote":1,"tweetType":1,"viewCount":26,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":162519132,"gmtCreate":1624067682826,"gmtModify":1703828036725,"author":{"id":"3586403806630485","authorId":"3586403806630485","name":"Tendious","avatar":"https://static.tigerbbs.com/0ec0679eb8bdffa05ed9e8b48dec1986","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586403806630485","authorIdStr":"3586403806630485"},"themes":[],"htmlText":"Good read. Cheers.&nbsp;","listText":"Good read. Cheers.&nbsp;","text":"Good read. Cheers.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/162519132","repostId":"2144775875","repostType":4,"repost":{"id":"2144775875","pubTimestamp":1624024260,"share":"https://ttm.financial/m/news/2144775875?lang=&edition=fundamental","pubTime":"2021-06-18 21:51","market":"us","language":"en","title":"Next Market Crash: 2 Top Growth Stocks to Buy Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2144775875","media":"Motley Fool","summary":"Don't wait to jump on this red-hot tech company and unstoppable dividend stock.","content":"<p>The state of the stock market in recent weeks hasn't been for the faint of heart. Whether the volatility investors are currently seeing actually foreshadows another market crash is anyone's guess, and trying to time the market to predict the best windows for buying stocks can be a recipe for disaster.</p>\n<p>No matter how worried you may be about a crash, it's always a great time to invest in high-quality stocks that generate wealth-building portfolio returns. To that end, let's take a look at two top stocks that can help your portfolio navigate the next market storm and provide meaningful sources of growth for years to come.</p>\n<h2>1. <a href=\"https://laohu8.com/S/FB\">Facebook</a></h2>\n<p><b>Facebook</b> (NASDAQ:FB) is hardly a new choice for long-term investors, but it's the type of stock you can add more of to your portfolio time and time again. The popular FAANG stock has gained approximately 25% since the beginning of 2021, and is up an eye-popping 41% compared to the same time last year.</p>\n<p>Facebook continues to control a massive share of the social media industry. According to Statista, \"Facebook accounted for nearly 71.8% of all social media site visits in the United States in May 2021.\" The company's ever-increasing market share is also driving exponential balance sheet growth.</p>\n<p>2020 was just another strong year in the books for Facebook, during which its total revenues increased 22% and its net income rose 58%. But Facebook's financial performance in the first quarter of 2021 left these figures in the dust. The company reported that its revenues surged 48% year over year during the three-month period.</p>\n<p>Facebook's net income grew by an even higher percentage -- a whopping 94% from the year-ago stretch. In addition, Facebook reported that its \"daily active users\" (what it calls daily Facebook users) and \"daily active people\" (what it calls daily users of any of Facebook's suite of products) surged by respective rates of 8% and 15% in the month of March alone.</p>\n<p>If you're wondering whether it's too late to buy Facebook on account of its upside potential, the answer is a resounding no. Facebook has plenty of juice left in it for long-term investors. And analysts currently estimate that the company can consistently deliver more than 20% average annual earnings growth for at least the next five years.</p>\n<p>After nearly two decades in business, Facebook continues to expand its market share and reassert its dominance of the social media sphere. This is a premium stock you can hold onto through both market highs and lows, <a href=\"https://laohu8.com/S/AONE\">one</a> that can generate consistent growth and maximize your portfolio returns.</p>\n<h2>2. AbbVie</h2>\n<p>Healthcare stock <b>AbbVie</b> (NYSE:ABBV) is another golden egg to have in your basket before the next market crash rolls around. AbbVie spun off from <b>Abbott Laboratories </b>in 2013, and its former parent company is a veteran member of the elite stock club known as Dividend Aristocrats.</p>\n<p>Stocks that snag the title of Dividend Aristocrats must raise their dividend for 25 consecutive years, and Abbott has done so for nearly 50. As a spinoff of Abbott, AbbVie is also considered a member of the Dividend Aristocrat club. It yields a robust 4.5% for investors at the time of this writing.</p>\n<p>The biggest concern some investors have about AbbVie is the looming loss of U.S. patent protection for its blockbuster drug Humira in 2023. Humira is an immunosuppressive drug used to treat a range of conditions from arthritis to Crohn's disease. It raked in more sales than any other drug in the entire world in 2020 -- amassing total net revenues just shy of $20 billion during the 12-month period.</p>\n<p>There's no doubt that AbbVie's balance sheet will reflect the loss of Humira's patent exclusivity in the U.S. in a few years. We need only look to AbbVie's loss of patent exclusivity in Europe -- which largely took effect in October 2018 -- as an example of this.</p>\n<p>Case in point: International sales of Humira were down 14% in 2020, but still totaled nearly $4 billion. In short, heightened competition in the U.S. will certainly detract from Humira's sales come 2023, but that doesn't mean that sales of the drug can't still inject healthy growth into AbbVie's balance sheet over the long term.</p>\n<p>It's also important to note that AbbVie has a rock-star portfolio of top-selling drugs besides Humira. These include plaque psoriasis drug Skyrizi, cancer drugs Imbruvica and Venclexta, and rheumatoid arthritis drug Rinvoq. Moreover, AbbVie's acquisition of Allergan last year ushered well-known product names like Botox into its portfolio of lucrative products.</p>\n<p>AbbVie's first-quarter 2021 revenues of $13 billion represented a huge 51% increase from the year-ago period. Breaking AbbVie's first-quarter performance down by its top business segments -- immunology, hematologic oncology, aesthetics (which includes Botox Cosmetic), and neuroscience (which includes Botox Therapeutic) -- these four divisions marked respective year-over-year revenue growth of 13%, 8%, 35%, and 100%.</p>\n<p>If you're looking for steady portfolio growth and attractive dividend income to anchor your portfolio in the next market storm, AbbVie offers shareholders the unbeatable combination of both.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Next Market Crash: 2 Top Growth Stocks to Buy Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNext Market Crash: 2 Top Growth Stocks to Buy Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-18 21:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/18/next-market-crash-101-2-top-growth-stocks-to-buy-r/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The state of the stock market in recent weeks hasn't been for the faint of heart. Whether the volatility investors are currently seeing actually foreshadows another market crash is anyone's guess, and...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/18/next-market-crash-101-2-top-growth-stocks-to-buy-r/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2021/06/18/next-market-crash-101-2-top-growth-stocks-to-buy-r/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2144775875","content_text":"The state of the stock market in recent weeks hasn't been for the faint of heart. Whether the volatility investors are currently seeing actually foreshadows another market crash is anyone's guess, and trying to time the market to predict the best windows for buying stocks can be a recipe for disaster.\nNo matter how worried you may be about a crash, it's always a great time to invest in high-quality stocks that generate wealth-building portfolio returns. To that end, let's take a look at two top stocks that can help your portfolio navigate the next market storm and provide meaningful sources of growth for years to come.\n1. Facebook\nFacebook (NASDAQ:FB) is hardly a new choice for long-term investors, but it's the type of stock you can add more of to your portfolio time and time again. The popular FAANG stock has gained approximately 25% since the beginning of 2021, and is up an eye-popping 41% compared to the same time last year.\nFacebook continues to control a massive share of the social media industry. According to Statista, \"Facebook accounted for nearly 71.8% of all social media site visits in the United States in May 2021.\" The company's ever-increasing market share is also driving exponential balance sheet growth.\n2020 was just another strong year in the books for Facebook, during which its total revenues increased 22% and its net income rose 58%. But Facebook's financial performance in the first quarter of 2021 left these figures in the dust. The company reported that its revenues surged 48% year over year during the three-month period.\nFacebook's net income grew by an even higher percentage -- a whopping 94% from the year-ago stretch. In addition, Facebook reported that its \"daily active users\" (what it calls daily Facebook users) and \"daily active people\" (what it calls daily users of any of Facebook's suite of products) surged by respective rates of 8% and 15% in the month of March alone.\nIf you're wondering whether it's too late to buy Facebook on account of its upside potential, the answer is a resounding no. Facebook has plenty of juice left in it for long-term investors. And analysts currently estimate that the company can consistently deliver more than 20% average annual earnings growth for at least the next five years.\nAfter nearly two decades in business, Facebook continues to expand its market share and reassert its dominance of the social media sphere. This is a premium stock you can hold onto through both market highs and lows, one that can generate consistent growth and maximize your portfolio returns.\n2. AbbVie\nHealthcare stock AbbVie (NYSE:ABBV) is another golden egg to have in your basket before the next market crash rolls around. AbbVie spun off from Abbott Laboratories in 2013, and its former parent company is a veteran member of the elite stock club known as Dividend Aristocrats.\nStocks that snag the title of Dividend Aristocrats must raise their dividend for 25 consecutive years, and Abbott has done so for nearly 50. As a spinoff of Abbott, AbbVie is also considered a member of the Dividend Aristocrat club. It yields a robust 4.5% for investors at the time of this writing.\nThe biggest concern some investors have about AbbVie is the looming loss of U.S. patent protection for its blockbuster drug Humira in 2023. Humira is an immunosuppressive drug used to treat a range of conditions from arthritis to Crohn's disease. It raked in more sales than any other drug in the entire world in 2020 -- amassing total net revenues just shy of $20 billion during the 12-month period.\nThere's no doubt that AbbVie's balance sheet will reflect the loss of Humira's patent exclusivity in the U.S. in a few years. We need only look to AbbVie's loss of patent exclusivity in Europe -- which largely took effect in October 2018 -- as an example of this.\nCase in point: International sales of Humira were down 14% in 2020, but still totaled nearly $4 billion. In short, heightened competition in the U.S. will certainly detract from Humira's sales come 2023, but that doesn't mean that sales of the drug can't still inject healthy growth into AbbVie's balance sheet over the long term.\nIt's also important to note that AbbVie has a rock-star portfolio of top-selling drugs besides Humira. These include plaque psoriasis drug Skyrizi, cancer drugs Imbruvica and Venclexta, and rheumatoid arthritis drug Rinvoq. Moreover, AbbVie's acquisition of Allergan last year ushered well-known product names like Botox into its portfolio of lucrative products.\nAbbVie's first-quarter 2021 revenues of $13 billion represented a huge 51% increase from the year-ago period. Breaking AbbVie's first-quarter performance down by its top business segments -- immunology, hematologic oncology, aesthetics (which includes Botox Cosmetic), and neuroscience (which includes Botox Therapeutic) -- these four divisions marked respective year-over-year revenue growth of 13%, 8%, 35%, and 100%.\nIf you're looking for steady portfolio growth and attractive dividend income to anchor your portfolio in the next market storm, AbbVie offers shareholders the unbeatable combination of both.","news_type":1},"isVote":1,"tweetType":1,"viewCount":37,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187002899,"gmtCreate":1623728228711,"gmtModify":1704209758360,"author":{"id":"3586403806630485","authorId":"3586403806630485","name":"Tendious","avatar":"https://static.tigerbbs.com/0ec0679eb8bdffa05ed9e8b48dec1986","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586403806630485","authorIdStr":"3586403806630485"},"themes":[],"htmlText":"Good buy like and comment!","listText":"Good buy like and comment!","text":"Good buy like and comment!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187002899","repostId":"1109511555","repostType":4,"repost":{"id":"1109511555","pubTimestamp":1623727571,"share":"https://ttm.financial/m/news/1109511555?lang=&edition=fundamental","pubTime":"2021-06-15 11:26","market":"us","language":"en","title":"Apple Plans Faster Watch, Future Temperature and Glucose Sensors","url":"https://stock-news.laohu8.com/highlight/detail?id=1109511555","media":"Bloomberg","summary":"Updated screens and performance this year, new functions later. New entry-level and extreme sports models planned for 2022. A customer tries on an Apple watch at a store in Palo Alto, California. Photographer: Nina Riggio/Bloomberg. Apple Inc. is working on new Apple Watch models and health features, spanning display and speed upgrades, an extreme sports edition and body temperature and blood sugar sensors.The Cupertino, California-based tech giant is planning to refresh the line this year -- wi","content":"<ul>\n <li>Updated screens and performance this year, new functions later</li>\n <li>New entry-level and extreme sports models planned for 2022</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e86dd58655f96500dda750d2b1350121\" tg-width=\"2000\" tg-height=\"1333\"><span>A customer tries on an Apple watch at a store in Palo Alto, California. Photographer: Nina Riggio/Bloomberg</span></p>\n<p>Apple Inc.&nbsp;is working on new Apple Watch models and health features, spanning display and speed upgrades, an extreme sports edition and body temperature and blood sugar sensors.</p>\n<p>The Cupertino, California-based tech giant is planning to refresh the line this year -- with a model likely dubbed the Apple Watch Series 7 -- by adding a faster processor, improved wireless connectivity and an updated screen, according to people with knowledge of the plans. Next year the company plans to update the main Apple Watch alongside a successor for the lower-end Apple Watch SE and a new version targeting extreme sports athletes.</p>\n<p>Apple had previously aimed to put a body temperature sensor in this year’s model, but that is now more likely to be included in the 2022 update. The blood-sugar sensor, which would help diabetics monitor their glucose levels, is unlikely to be ready for commercial launch for several more years.</p>\n<p>For this year’s model, Apple has tested thinner display borders and a new lamination technique that brings the display closer to the front cover. The new Watch is likely to be slightly thicker overall, but not in a way that’s noticeable to the user.</p>\n<p>The model will include updated ultra-wideband functionality, the same underlying technology in the Apple AirTag item finder. At its developer conference in early June, Apple previewed the upcoming watchOS 8 software update that will let the device unlock door and hotel rooms.</p>\n<p>The extreme sports model, described by some inside Apple as either an “explorer” or “adventure” edition, was in development for release as early as this year, but it is now more likely to launch in 2022. That new model would help Apple compete with rugged offerings from players like&nbsp;Garmin Ltd.&nbsp;and&nbsp;Casio Computer Co.</p>\n<p>An Apple spokeswoman declined to comment. The company’s plans remain fluid and could change, the people said.</p>\n<p>Luxshare Precision Industry Co.&nbsp;is the primary assembler for the main Apple Watch, while&nbsp;Hon Hai Precision Industry Co., or Foxconn, shares some of those orders in addition to splitting assembly of the Apple Watch SE with Taiwan’s&nbsp;Compal Electronics Inc.</p>\n<p>Measuring body temperature became an essential part of Covid-19 detection, prompting a&nbsp;surge&nbsp;in demand for gadgets such as the&nbsp;Withings Thermo. Some companies offer small digital thermometers that plug into a smartphone’s charging port. Adding the functionality into its watch would help Apple match other smartwatches and fitness bands, including products from&nbsp;Alphabet Inc.-owned&nbsp;Fitbit.</p>\n<p>Blood sugar monitoring has been long in the works at Apple and would be a feature thus far unrivaled by competitors. Apple and others currently rely on apps that let users input their glucose levels manually, while medical device companies like&nbsp;Dexcom Inc.&nbsp;offer blood sugar monitors that share data with the Apple Watch. Users typically need to prick their finger to draw blood for an accurate glucose test, but Apple is aiming for a non-invasive solution that can analyze blood through the skin.</p>\n<p>Since going on sale in 2015, the Apple Watch has grown into a key part of Apple’s product portfolio. Along with the iPhone and iPad, it fills out the company’s hardware ecosystem and helped Apple’s broader wearables, home and accessories category generate more than $30 billion last fiscal year.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple Plans Faster Watch, Future Temperature and Glucose Sensors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple Plans Faster Watch, Future Temperature and Glucose Sensors\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-15 11:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-06-14/apple-plans-faster-watch-future-temperature-and-glucose-sensors><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Updated screens and performance this year, new functions later\nNew entry-level and extreme sports models planned for 2022\n\nA customer tries on an Apple watch at a store in Palo Alto, California. ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-06-14/apple-plans-faster-watch-future-temperature-and-glucose-sensors\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://www.bloomberg.com/news/articles/2021-06-14/apple-plans-faster-watch-future-temperature-and-glucose-sensors","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1109511555","content_text":"Updated screens and performance this year, new functions later\nNew entry-level and extreme sports models planned for 2022\n\nA customer tries on an Apple watch at a store in Palo Alto, California. Photographer: Nina Riggio/Bloomberg\nApple Inc. is working on new Apple Watch models and health features, spanning display and speed upgrades, an extreme sports edition and body temperature and blood sugar sensors.\nThe Cupertino, California-based tech giant is planning to refresh the line this year -- with a model likely dubbed the Apple Watch Series 7 -- by adding a faster processor, improved wireless connectivity and an updated screen, according to people with knowledge of the plans. Next year the company plans to update the main Apple Watch alongside a successor for the lower-end Apple Watch SE and a new version targeting extreme sports athletes.\nApple had previously aimed to put a body temperature sensor in this year’s model, but that is now more likely to be included in the 2022 update. The blood-sugar sensor, which would help diabetics monitor their glucose levels, is unlikely to be ready for commercial launch for several more years.\nFor this year’s model, Apple has tested thinner display borders and a new lamination technique that brings the display closer to the front cover. The new Watch is likely to be slightly thicker overall, but not in a way that’s noticeable to the user.\nThe model will include updated ultra-wideband functionality, the same underlying technology in the Apple AirTag item finder. At its developer conference in early June, Apple previewed the upcoming watchOS 8 software update that will let the device unlock door and hotel rooms.\nThe extreme sports model, described by some inside Apple as either an “explorer” or “adventure” edition, was in development for release as early as this year, but it is now more likely to launch in 2022. That new model would help Apple compete with rugged offerings from players like Garmin Ltd. and Casio Computer Co.\nAn Apple spokeswoman declined to comment. The company’s plans remain fluid and could change, the people said.\nLuxshare Precision Industry Co. is the primary assembler for the main Apple Watch, while Hon Hai Precision Industry Co., or Foxconn, shares some of those orders in addition to splitting assembly of the Apple Watch SE with Taiwan’s Compal Electronics Inc.\nMeasuring body temperature became an essential part of Covid-19 detection, prompting a surge in demand for gadgets such as the Withings Thermo. Some companies offer small digital thermometers that plug into a smartphone’s charging port. Adding the functionality into its watch would help Apple match other smartwatches and fitness bands, including products from Alphabet Inc.-owned Fitbit.\nBlood sugar monitoring has been long in the works at Apple and would be a feature thus far unrivaled by competitors. Apple and others currently rely on apps that let users input their glucose levels manually, while medical device companies like Dexcom Inc. offer blood sugar monitors that share data with the Apple Watch. Users typically need to prick their finger to draw blood for an accurate glucose test, but Apple is aiming for a non-invasive solution that can analyze blood through the skin.\nSince going on sale in 2015, the Apple Watch has grown into a key part of Apple’s product portfolio. Along with the iPhone and iPad, it fills out the company’s hardware ecosystem and helped Apple’s broader wearables, home and accessories category generate more than $30 billion last fiscal year.","news_type":1},"isVote":1,"tweetType":1,"viewCount":85,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"followers","isTTM":true}